期刊文献+

巨噬细胞移动抑制因子在系统性红斑狼疮中的研究进展 被引量:2

Research Progress of Macrophage Migration Inhibitory Factor in Systemic Lupus Erythematosus
在线阅读 下载PDF
导出
摘要 系统性红斑狼疮(SLE)是一种病因未明的慢性多系统自身免疫性疾病,遗传、激素和某些环境因素均与SLE的发病有关。SLE复发和缓解交替出现,病程复杂,目前的药物治疗可减少或延缓疾病的进展和器官损害,尚无法治愈。巨噬细胞移动抑制因子(MIF)是一种具有广泛免疫调节特性的多功能蛋白质,能够通过激活巨噬细胞功能、活化淋巴细胞、促进某些细胞因子的分泌和表达等途径参与SLE的发生和发展。因此,MIF可能成为自身免疫性疾病的治疗靶点,在临床应用上具有很大的潜力,但未来仍需要更深入的研究来证实其安全性和有效性。 Systemic lupus erythematosus(SLE) is a typical chronic autoimmune disease involving multiple systemic damages.It is generally considered a multifactorial disease,as a combination of genetics,hormones,environmental triggers,and other factors. SLE recurrences and remissions occur alternately,and the course of disease is complex Current medication can only reduce/delay the disease progression and organ damages,but achieves no cure.Macrophage migration inhibitory factor(MIF) is a multifunctional protein with a broad range of immunomodulatory properties,which participates in the deve-lopment of SLE mainly by activating macrophage and lymphocytes,and promoting the secretion and expression of certain cytokines .Therefore,MIF may become one therapeutic target for the autoimmune disease and has a great potential in the clinical application,though larger studies are still needed to confirm the safety and efficacy in the future.
作者 黄宇 曲航 黄琴 HUANG Yu;QU Hang;HUANG Qin(The Second School of Clinical Medicine,Southern Medical University,Guangzhou 510515,China;Department of Rheumatology,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China)
出处 《医学综述》 2020年第3期433-437,442,共6页 Medical Recapitulate
基金 国家自然科学基金(81801624) 广东省医学科学技术研究基金项目(A2019020) 南方医科大学大学生创新计划项目(201812121288)
关键词 系统性红斑狼疮 巨噬细胞移动抑制因子 基因多态性 免疫 Systemic lupus erythematosus Macrophage migration inhibitory factor Gene polymorphism Immune
  • 相关文献

参考文献2

二级参考文献83

  • 1陈伟英,李广然,方芳,阳晓,何新生,周飞宇,余学清.外周血单个核细胞巨噬细胞移动抑制因子表达及其与狼疮活动[J].中华内科杂志,2004,43(8):572-575. 被引量:10
  • 2Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum, 1992, 35: 630-640.
  • 3Waeber G, Calandra T, Bonny C, et al. A role for the endocrine and proinflammatory mediator MIF in the control of insulin secretion during stress. Diabetes Metab Res Rev, 1999, 15: 47-54.
  • 4Baugh JA, Bucala R. Macrophage migration inhibitory factor. Crit Care Med, 2002, 30: 27-35.
  • 5Sanchez E, Gomez LM, Lopez-Nevot MA, et al. Evidence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus. Genes Immun, 2006, 7: 433-436.
  • 6Foote A, Briganti EM, Kipen Y, et al. Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol, 2004, 31: 268-273.
  • 7Ikezumi Y, Hurst LA, Masaki T, et al. Adoptive transfer studies demonstrate that macrophage can induce proteinuria and mesangial cell proliferation. Kidney Int, 2003, 63: 83.
  • 8Hoi AY, Hickey M J, Hall P, et al. Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. J Immunol. 2006, 177: 5687-5696.
  • 9Onodera S, Nishihira J, Koyama Y, et al. Macrophage migration inhibitory factor up-regulates the expression of interleukin-8 messenger RNA in synovial fibroblasts of rheumatoid arthritis patients: common transcriptional regulatory mechanism between interleukin-8 and interleukin-1 beta. Arthritis Rheum, 2004, 50: 1437-1447.
  • 10Morand EF, Leech M, Weedon H, et al. Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations. J Rheumatol, 2002, 41: 558-562.

共引文献13

同被引文献18

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部